Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long Term Follow-Up of Participants Exposed to GSK3377794 (NY-ESO-1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor

Trial Profile

Long Term Follow-Up of Participants Exposed to GSK3377794 (NY-ESO-1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs GSK 3377794 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Adaptimmune
  • Most Recent Events

    • 12 Oct 2018 Planned number of patients changed from 300 to 200.
    • 12 Oct 2018 Planned End Date changed from 1 May 2047 to 1 Apr 1932.
    • 12 Oct 2018 Planned primary completion date changed from 1 May 2047 to 1 Apr 1932.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top